Беротек (fenoterol) is a prescribed medication used to assist with conditions that cause the narrowing of airways. Its primary therapeutic role is to help relax the muscles in the air passages, which may help support easier breathing for individuals who need it.

Quick Facts: Uses of Беротек

• Assists with: Acute episodes of breathing difficulty in asthma.
• Helps manage: Symptoms in individuals with chronic obstructive bronchitis and other conditions involving reversible airway obstruction.
• May be used for: Prevention of exercise-induced breathing difficulty.

It is an established treatment option in the management of respiratory conditions where opening the airways is a key component of relief.

Regulatory References

1. Irish Medicines Board (HPRA) regulatory overview

Absolute Contraindications (Must Not Use)

The use of Беротек (Fenoterol hydrobromide) is contraindicated (absolutely prohibited) for specific populations as stated in official regulatory documents. This includes individuals diagnosed with hypertrophic obstructive cardiomyopathy or tachyarrhythmia. The medicine is also strictly prohibited for patients with a known hypersensitivity to fenoterol hydrobromide or to any of the product's excipients.

Conditional Use and Restrictions

Eligibility is restricted and requires careful medical risk assessment for several patient populations, particularly when higher-than-recommended doses are considered. Use is conditional in patients with insufficiently controlled diabetes mellitus, severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma, or those with a history of recent myocardial infarction.

Age and Reproductive Status

The medicine is established for use in adults and adolescents. Pediatric eligibility is documented for children aged six years and older (metered-dose inhaler form), with use limited in children below this age. The official label notes that no specific information on use is available for the elderly population. For pregnant women, caution is advised, especially during the first trimester. Caution is similarly advised for nursing mothers, as fenoterol is documented to be excreted into breast milk.

Interactions with other medicines and products

The interaction profile for Fenoterol (the active ingredient in Беротек) is defined by pharmacodynamic effects and altered systemic sensitivity, based on regulatory documentation.

---

Interacting Product Classes and Patterns

Category	Interaction Pattern
beta-Blockers (Non-selective)	Documented to cause a potentially serious reduction in bronchodilatation due to antagonism of the beta2-agonist effect.
Sympathomimetics / Xanthine Derivatives	Co-administration with other beta-adrenergics or Xanthine derivatives (e.g., Theophylline) may enhance the bronchodilatatory effect but also increase the risk of adverse reactions.
Psychoactive Agents	Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may enhance the action of beta-adrenergic agonists, leading to a potential increase in cardiovascular side effects.
Hypokalaemia-Inducing Agents	Corticosteroids, Diuretics, and Xanthine derivatives increase the risk of beta2-agonist-induced hypokalaemia. This condition, if present, increases the patient's susceptibility to arrhythmias when co-administered with Digoxin.
Anesthetics	Halogenated hydrocarbon anaesthetics (e.g., Halothane) may increase susceptibility to the cardiovascular effects of beta-agonists.

---

The regulatory profile indicates that all interactions are based on functional outcomes, with no mandatory timing separation rules or documentation of specific food, alcohol, or CYP enzyme-mediated pharmacokinetic interactions.

How Беротек Works (Fenoterol Hydrobromide)

Fenoterol hydrobromide functions as a selective agonist at the Beta-2 Adrenoreceptors (beta2-AR) highly expressed on bronchial smooth muscle cells. This binding initiates a G-protein-mediated signal cascade, activating the enzyme adenylate cyclase to increase the intracellular concentration of the secondary messenger, cyclic AMP (cAMP). The elevated cAMP activates Protein Kinase A (PKA), which phosphorylates and functionally inactivates Myosin Light-Chain Kinase (MLCK), the enzyme responsible for initiating muscle contraction. This molecular sequence produces the relaxation of airway smooth muscle, resulting in the widening of the bronchial lumen.

Activation also extends to beta2-ARs on mast cells, causing the stabilization of cell membranes and reducing the acute release of bronchoconstricting mediators. Due to relative selectivity, the molecule also acts on cardiac beta1-Adrenoreceptors, leading to a predictable change in myocardial chronotropy and inotropy. Mechanistic efficacy is constrained by factors like receptor desensitization upon repeated stimulation and potential oxidative degradation in highly inflamed tissue.

Official Administration Guidelines

Беротек (fenoterol hydrobromide) is administered exclusively via the pulmonary route, utilizing either a pressurised Metered-Dose Inhaler (MDI) or an inhalation solution intended for delivery via a nebulizer.

Dosing and Frequency

Usage is primarily on-demand (as-needed) for acute symptomatic relief; it is not intended for regular, long-term maintenance.

Usage Scenario	Standard Regimen (MDI 100 µg/puff)	Daily Maximum
Acute Symptom Relief	Initial dose of 1 puff; may repeat after 5 minutes if relief is inadequate.	8 puffs
Prophylaxis	1 to 2 puffs prior to activity.	8 puffs

Preparation and Special Conditions

Proper use requires specific technical steps. A new MDI must be primed by depressing the valve twice before the first use. If the product is the inhalation solution, it must be diluted only with sterile physiological saline (0.9% NaCl) immediately prior to nebulization. For pediatric patients, the administration of the metered aerosol occurs under the supervision of an adult. The patient must adhere to the correct inhalation technique, which includes holding the breath for a few seconds following the dose to ensure optimal delivery.

Research Evidence / Overview of Studies for Беротек

Evidence for Rapid Relief of Acute Breathing Difficulty

Research exploring Беротек includes short-term Randomized Controlled Trials (RCTs) evaluating the medication in situations of sudden or episodic breathing difficulties. These studies were applied in research contexts involving fluctuating or unstable symptoms, where researchers examined how symptoms change over defined, short time intervals. The trials typically included adults and children (from age 6) experiencing acute phases of bronchial obstruction.

In these research scenarios, studies monitored outcomes such as the rapid change in functional measures like FEV1 (Forced Expiratory Volume in 1 second) and PEF (Peak Expiratory Flow), which are relevant in evidence describing how symptoms are measured. The findings describe patterns observed in the studies related to immediate changes in functional measurements within the airways.

Evidence for Managing Chronic Reversible Airway Conditions

Беротек was also evaluated in studies examining patient-reported experiences related to conditions characterized by fluctuating or episodic manifestations, such as chronic obstructive bronchitis and COPD. Research explored short-term symptom changes when the medicine was studied for periods of regular administration, rather than for acute relief alone.

These studies monitored physiological strain or stress, and outcomes related to physical discomfort over intermediate time frames, such as 4 to 12 weeks. Findings indicate patterns related to measured changes in lung function and reported symptom levels over the observation period in the studied populations. However, the evidence quality varies across studies when compared to evidence for acute relief.

Long-Term Evidence, Observational Data, and Follow-up

Regulatory Examination of Long-Term Patterns

Beyond the standard clinical trials, the research landscape includes historical large-scale observational cohorts and retrospective analyses. Data show patterns related to use—specifically, evidence suggests a historic association between high-use patterns observed in certain studies and an observed increase in certain adverse events. This finding was associated with systematic regulatory examination by governmental bodies, leading to a reassessment of labeling and the need for stringent prescribing controls. The evidence base is complex, and certainty remains low regarding absolute long-term safety profiles.

Key Studies & References

1. WHO ATC/DDD Index: R03AC04 - Fenoterol
2. Irish Medicines Board (HPRA) Summary of Product Characteristics (SPC) for Berotec 100

Common questions about Беротек (FAQ)

---

Q: Does Беротек (Fenoterol) need to be prescribed by a doctor?

According to official product information, Беротек is a medication that requires a prescription from a healthcare professional for its use. Regulatory labeling indicates that the use of this medication requires the assessment and authorization of a qualified healthcare professional.

---

Q: What is the primary action of the active substance in Беротек?

The active substance in Беротек is Fenoterol, which belongs to a class of drugs called selective beta2-agonists. This substance is designed to work by relaxing the smooth muscles in the bronchial tubes, which are the airways in the lungs. This action is intended to help open up the airways and assist in making breathing easier.

---

Q: Can I use Беротек if I have other heart conditions like cardiac arrhythmia?

Official regulatory documents indicate that Беротек should be used with caution, or may be contraindicated, in patients with certain pre-existing heart conditions. These conditions may include an abnormally rapid heart rate, severe heart valve issues, and some types of irregular heart rhythm (cardiac arrhythmia). Official prescribing information requires healthcare providers to consider any existing heart conditions before prescribing this medicine.

---

Q: Is Беротек effective for treating asthma attacks and other conditions with reversible airway obstruction?

Yes, regulatory sources state that Беротек is indicated for the symptomatic treatment of acute asthma attacks. It is also used to manage other conditions associated with reversible narrowing of the airways, such as chronic obstructive pulmonary disease (COPD). Its intended action is to help relieve symptoms of acute airway obstruction, such as shortness of breath and wheezing.

---

Q: Are there any side effects related to heart rate or heart rhythm when using Беротек?

According to the official product information, side effects involving the cardiovascular system have been reported with Беротек. These potential effects may include changes in heart rate (tachycardia), irregular heart rhythm (arrhythmias), and a condition where the heart muscle has insufficient blood flow (myocardial ischemia). Regulatory documents state that any concerns about these potential effects should be addressed by a healthcare professional.

---

Q: How quickly does Беротек start to work after administration?

Studies and official information indicate that Беротек has a rapid onset of action when used for acute airway constriction. Its therapeutic effect on the airways typically begins shortly after inhalation. The rapid onset of action supports its use for the management of acute breathing difficulties associated with reversible airway disease.

---

Q: What happens if I use Беротек more often than prescribed?

Official regulatory documents caution against exceeding the prescribed dose or frequency of use for Беротек. Overuse may be associated with a worsening of the underlying condition or an increased risk of severe adverse effects. If a patient feels the need to use the medication more often than directed, the official product labeling advises immediate consultation with the prescribing physician.

---

Storage Conditions

The Berotec metered-dose inhaler must be stored below 25 C and should be protected from direct sunlight, heat, and frost. The product must be stored out of the sight and reach of children to prevent unauthorized access.

Canister Handling and Protection

The aluminum canister is pressurized and requires careful handling. It must not be dropped, punctured, or incinerated, even when empty. The canister should also not be exposed to temperatures above 50 C, as this could cause it to burst.

Disposal Instructions

Disposal of any unused medicine or waste material must strictly adhere to local regulatory requirements. To protect the environment, the product and contaminated waste should not be flushed into surface water or the sanitary sewer system.